{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "https://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&hansardHeading=HIV+Infection%3A+Drugs&max-answer.dateOfAnswer=2018-11-20", "definition" : "https://eldaddp.azurewebsites.net/meta/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&hansardHeading=HIV+Infection%3A+Drugs&max-answer.dateOfAnswer=2018-11-20", "extendedMetadataVersion" : "https://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&_metadata=all&hansardHeading=HIV+Infection%3A+Drugs&max-answer.dateOfAnswer=2018-11-20", "first" : "https://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&_page=0&hansardHeading=HIV+Infection%3A+Drugs&max-answer.dateOfAnswer=2018-11-20", "hasPart" : "https://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&hansardHeading=HIV+Infection%3A+Drugs&max-answer.dateOfAnswer=2018-11-20", "isPartOf" : "https://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&hansardHeading=HIV+Infection%3A+Drugs&max-answer.dateOfAnswer=2018-11-20", "items" : [{"_about" : "http://data.parliament.uk/resources/1007772", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1007772/answer", "answerText" : {"_value" : "<p>In line with the guidance governing research, the HIV Pre-Exposure Prophylaxis (PrEP) Impact Trial is currently unable to provide any detailed breakdown of information about participants. This is to preserve the integrity of the emerging data. A planned interim analysis including further demographic breakdown is planned early next year.<\/p><p> <\/p><p>An evaluation report will be available after the completion of the trial in 2021 which is expected to include the facilitators and barriers to accessing HIV pre-exposure prophylaxis across all groups, including women.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-11-20", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "191930"}
        , {"_value" : "191931"}
        , {"_value" : "191932"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-11-20T15:03:05.303Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-11-15", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "HIV Infection: Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2018 to Question 153280 on HIV Infection: Drugs, if he will publish the review of risk factors and associated vulnerabilities among women recruited to the trial.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4267", "label" : {"_value" : "Biography information for Sarah Champion"}
      }
      , "tablingMemberConstituency" : {"_value" : "Rotherham"}
      , "tablingMemberPrinted" : [{"_value" : "Sarah Champion"}
      ], "uin" : "191929"}
    , {"_about" : "http://data.parliament.uk/resources/1007773", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1007773/answer", "answerText" : {"_value" : "<p>In line with the guidance governing research, the HIV Pre-Exposure Prophylaxis (PrEP) Impact Trial is currently unable to provide any detailed breakdown of information about participants. This is to preserve the integrity of the emerging data. A planned interim analysis including further demographic breakdown is planned early next year.<\/p><p> <\/p><p>An evaluation report will be available after the completion of the trial in 2021 which is expected to include the facilitators and barriers to accessing HIV pre-exposure prophylaxis across all groups, including women.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-11-20", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "191929"}
        , {"_value" : "191931"}
        , {"_value" : "191932"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-11-20T15:03:05.35Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-11-15", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "HIV Infection: Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2018 to Question 153280 on HIV Infection: drugs, if he will publish the outcome of the interviews with women to explore the facilitators and barriers to accessing the HIV pre-exposure prophylaxis.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4267", "label" : {"_value" : "Biography information for Sarah Champion"}
      }
      , "tablingMemberConstituency" : {"_value" : "Rotherham"}
      , "tablingMemberPrinted" : [{"_value" : "Sarah Champion"}
      ], "uin" : "191930"}
    , {"_about" : "http://data.parliament.uk/resources/1007775", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1007775/answer", "answerText" : {"_value" : "<p>In line with the guidance governing research, the HIV Pre-Exposure Prophylaxis (PrEP) Impact Trial is currently unable to provide any detailed breakdown of information about participants. This is to preserve the integrity of the emerging data. A planned interim analysis including further demographic breakdown is planned early next year.<\/p><p> <\/p><p>An evaluation report will be available after the completion of the trial in 2021 which is expected to include the facilitators and barriers to accessing HIV pre-exposure prophylaxis across all groups, including women.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-11-20", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "191929"}
        , {"_value" : "191930"}
        , {"_value" : "191932"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-11-20T15:03:05.407Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-11-15", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "HIV Infection: Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2018 to Question 153280 on HIV Infection: Drugs, how many women have joined the HIV pre-exposure prophylaxis impact trial to date.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4267", "label" : {"_value" : "Biography information for Sarah Champion"}
      }
      , "tablingMemberConstituency" : {"_value" : "Rotherham"}
      , "tablingMemberPrinted" : [{"_value" : "Sarah Champion"}
      ], "uin" : "191931"}
    , {"_about" : "http://data.parliament.uk/resources/1007776", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1007776/answer", "answerText" : {"_value" : "<p>In line with the guidance governing research, the HIV Pre-Exposure Prophylaxis (PrEP) Impact Trial is currently unable to provide any detailed breakdown of information about participants. This is to preserve the integrity of the emerging data. A planned interim analysis including further demographic breakdown is planned early next year.<\/p><p> <\/p><p>An evaluation report will be available after the completion of the trial in 2021 which is expected to include the facilitators and barriers to accessing HIV pre-exposure prophylaxis across all groups, including women.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-11-20", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "191929"}
        , {"_value" : "191930"}
        , {"_value" : "191931"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-11-20T15:03:05.453Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-11-15", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "HIV Infection: Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2018 to Question 153280 on HIV Infection: Drugs, how many women who are victims of domestic violence have joined the HIV pre-exposure prophylaxis impact trial to date.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4267", "label" : {"_value" : "Biography information for Sarah Champion"}
      }
      , "tablingMemberConstituency" : {"_value" : "Rotherham"}
      , "tablingMemberPrinted" : [{"_value" : "Sarah Champion"}
      ], "uin" : "191932"}
    , {"_about" : "http://data.parliament.uk/resources/994107", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/994107/answer", "answerText" : {"_value" : "<p>Public Health England publishes data on the time interval between diagnosis of HIV and initiation of treatment. Latest available data show that in 2016 in the United Kingdom, 76% (3,214/4,225) of people newly diagnosed with HIV started treatment within 90 days of diagnosis.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-11-01", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-11-01T16:37:22.367Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-10-24", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "HIV Infection: Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will publish data on the average period of time between a diagnosis of HIV and initiation on antiretroviral therapy in the most recent year for which data is available.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4244", "label" : {"_value" : "Biography information for Jonathan Ashworth"}
      }
      , "tablingMemberConstituency" : {"_value" : "Leicester South"}
      , "tablingMemberPrinted" : [{"_value" : "Jonathan Ashworth"}
      ], "uin" : "183408"}
    , {"_about" : "http://data.parliament.uk/resources/994111", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/994111/answer", "answerText" : {"_value" : "<p>Data is not available to inform an assessment of the level of adherence to NHS England\u2019s Clinical Commissioning Policy on immediate antiretroviral therapy for treatment of HIV-1 in adults and adolescents. This data will be published in 2019.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-11-01", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-11-01T16:49:48.707Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-10-24", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "HIV Infection: Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the level of adherence to NHS England\u2019s Clinical Commissioning Policy on immediate antiretroviral therapy for treatment of HIV-1 in adults and adolescents since its publication in March 2018.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4244", "label" : {"_value" : "Biography information for Jonathan Ashworth"}
      }
      , "tablingMemberConstituency" : {"_value" : "Leicester South"}
      , "tablingMemberPrinted" : [{"_value" : "Jonathan Ashworth"}
      ], "uin" : "183409"}
    , {"_about" : "http://data.parliament.uk/resources/947436", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/947436/answer", "answerText" : {"_value" : "<p>Central government does not commission HIV, sexual health or prevention services directly. NHS England is funding the three year HIV pre-exposure prophylaxis (PrEP) Impact trial which will provide NHS England and local authority commissioners with data to inform the future commissioning of a clinically and cost effective PrEP programme. The trial began in October 2017 and full results will be available in early 2021. NHS England and local authority commissioners are already working together to use the provisional information generated by the trial to begin work to prepare for future commissioning of PrEP.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-09-06", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-09-06T16:06:56.55Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-07-24", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "HIV Infection: Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, if the Government will make it its policy to fund PrEP from central government funding for all at risk groups.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1489", "label" : {"_value" : "Biography information for Dawn Butler"}
      }
      , "tablingMemberConstituency" : {"_value" : "Brent Central"}
      , "tablingMemberPrinted" : [{"_value" : "Dawn Butler"}
      ], "uin" : "167927"}
    , {"_about" : "http://data.parliament.uk/resources/934317", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/934317/answer", "answerText" : {"_value" : "<p>As of 28 June 2018, 7,893 participants have been enrolled in the pre-exposure prophylaxis (PrEP) Impact Trial at 140 clinics across England. Information on participating clinics and enrolment status is regularly updated on the PreP Impact Trial website at the following link:<\/p><p><a href=\"https://www.prepimpacttrial.org.uk/join-the-trial\" target=\"_blank\">https://www.prepimpacttrial.org.uk/join-the-trial<\/a><\/p><p>A reallocation of spaces took place in May 2018 meaning 139 of the clinics are open to recruitment for gay and bisexual men with a number of the reallocated places being held centrally by the trial sponsor, so that clinics can request more if they are approaching their full allocation of places.<\/p><p>A proposal is also being assessed to consider increasing the total number of places available for the trial from 10,000 to 13,000. Work has begun with commissioners to prepare for future commissioning arrangements. More information on these developments can be found at the following link:<\/p><p><a href=\"https://www.england.nhs.uk/commissioning/spec-services/npc-crg/blood-and-infection-group-f/f03/prep-trial-updates/\" target=\"_blank\">https://www.england.nhs.uk/commissioning/spec-services/npc-crg/blood-and-infection-group-f/f03/prep-trial-updates/<\/a><\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-07-09", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-07-09T16:18:57.753Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-07-03", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "HIV Infection: Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what progress has been made on the PrEP drugs trail; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4412", "label" : {"_value" : "Biography information for Dr Lisa Cameron"}
      }
      , "tablingMemberConstituency" : {"_value" : "East Kilbride, Strathaven and Lesmahagow"}
      , "tablingMemberPrinted" : [{"_value" : "Dr Lisa Cameron"}
      ], "uin" : "160261"}
    , {"_about" : "http://data.parliament.uk/resources/923297", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/923297/answer", "answerText" : {"_value" : "<p>The HIV pre-exposure prophylaxis (PrEP) Impact Trial Team works together with the Trial Community Advisory Board to address issues regarding barriers to recruitment. A number of workstreams are ongoing or planned to specifically address access to the trial by women. These include a review of risk factors and associated vulnerabilities among women recruited to the trial; interviews with women to explore the facilitators and barriers to accessing PrEP; and mapping of activities across the country relating to PrEP awareness-raising among key populations including women.<\/p><p> <\/p><p>Through Public Health England\u2019s HIV Prevention Innovation Fund, three PrEP initiatives have been funded that aim to raise awareness in underserved communities, including women.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-06-21", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-06-21T16:06:35.843Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-06-13", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "HIV Infection: Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 26 April 2018 to question 136402 on HIV Infection: Drugs, if he will he make an assessment of the potential barriers to joining the PrEP Impact trial for women who are victims of domestic violence.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4267", "label" : {"_value" : "Biography information for Sarah Champion"}
      }
      , "tablingMemberConstituency" : {"_value" : "Rotherham"}
      , "tablingMemberPrinted" : [{"_value" : "Sarah Champion"}
      ], "uin" : "153280"}
    , {"_about" : "http://data.parliament.uk/resources/919104", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/919104/answer", "answerText" : {"_value" : "<p>NHS England holds the direct commissioning responsibility for HIV drugs, and the commissioning of antiretroviral drugs is undertaken by the Specialised Commissioning teams within NHS England.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-06-14", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-06-14T11:04:45.957Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-06-07", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "HIV Infection: Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, which part of the NHS is responsible for HIV commissioning for the provision of drugs.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
      }
      , "tablingMemberConstituency" : {"_value" : "Strangford"}
      , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
      ], "uin" : "151164"}
    ], "itemsPerPage" : 10, "next" : "https://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&_page=1&hansardHeading=HIV+Infection%3A+Drugs&max-answer.dateOfAnswer=2018-11-20", "page" : 0, "startIndex" : 1, "totalResults" : 19, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}